Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB pathways.
Xiang XuHu-Nan PiaoFumie AosaiXiao-Yu ZengJia-Hui ChengYue-Xian CuiJing LiJuan MaHu-Ri PiaoXuejun JinLian Xun PiaoPublished in: British journal of pharmacology (2020)
Arctigenin has antidepressant-like effects by attenuating excessive microglial activation and neuroinflammation through the HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB signalling pathways. This suggests that arctigenin has potential as a new drug candidate suitable for clinical trials to treat depression.
Keyphrases
- lps induced
- inflammatory response
- signaling pathway
- lipopolysaccharide induced
- toll like receptor
- nuclear factor
- clinical trial
- rheumatoid arthritis
- pi k akt
- immune response
- major depressive disorder
- sleep quality
- cell proliferation
- bipolar disorder
- spinal cord
- spinal cord injury
- weight gain
- brain injury
- blood brain barrier
- adverse drug
- subarachnoid hemorrhage